18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.
暂无分享，去创建一个
G. Linette | K. Lewis | C. Lebbé | M. Milella | P. Nghiem | J. Russell | P. Terheyden | I. Zwiener | O. Hamid | S. Bhatia | J. Mehnert | I. Brownell | M. Bajars | K. Shih | S. D’Angelo | M. Hennessy